X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC PHARMA SUN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 37.7 27.4 137.7% View Chart
P/BV x 4.0 5.5 72.9% View Chart
Dividend Yield % 0.3 0.6 51.0%  

Financials

 SUN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ALEMBIC PHARMA
Mar-18
SUN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs701645 108.6%   
Low Rs433470 92.2%   
Sales per share (Unadj.) Rs110.4166.1 66.5%  
Earnings per share (Unadj.) Rs11.021.9 50.1%  
Cash flow per share (Unadj.) Rs17.227.5 62.7%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.40.7 49.2%  
Book value per share (Unadj.) Rs158.8117.8 134.8%  
Shares outstanding (eoy) m2,399.26188.52 1,272.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 153.0%   
Avg P/E ratio x51.625.5 202.8%  
P/CF ratio (eoy) x32.920.3 162.3%  
Price / Book Value ratio x3.64.7 75.4%  
Dividend payout %18.218.3 99.7%   
Avg Mkt Cap Rs m1,360,021105,090 1,294.1%   
No. of employees `00017.8NA-   
Total wages/salary Rs m53,6716,228 861.7%   
Avg. sales/employee Rs Th14,890.9NM-  
Avg. wages/employee Rs Th3,017.1NM-  
Avg. net profit/employee Rs Th1,480.6NM-  
INCOME DATA
Net Sales Rs m264,89531,308 846.1%  
Other income Rs m8,38870 11,931.2%   
Total revenues Rs m273,28231,378 870.9%   
Gross profit Rs m56,0816,431 872.1%  
Depreciation Rs m14,9981,055 1,422.2%   
Interest Rs m5,17634 15,222.6%   
Profit before tax Rs m44,2955,413 818.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,204 702.3%   
Profit after tax Rs m26,3384,128 638.0%  
Gross profit margin %21.220.5 103.1%  
Effective tax rate %19.122.2 85.8%   
Net profit margin %9.913.2 75.4%  
BALANCE SHEET DATA
Current assets Rs m316,35918,247 1,733.7%   
Current liabilities Rs m198,64311,235 1,768.1%   
Net working cap to sales %44.422.4 198.4%  
Current ratio x1.61.6 98.1%  
Inventory Days Days9586 110.8%  
Debtors Days Days10861 175.5%  
Net fixed assets Rs m213,17820,035 1,064.0%   
Share capital Rs m2,399377 636.4%   
"Free" reserves Rs m378,60621,824 1,734.8%   
Net worth Rs m381,00622,201 1,716.1%   
Long term debt Rs m17,7215,000 354.4%   
Total assets Rs m643,02839,411 1,631.6%  
Interest coverage x9.6160.2 6.0%   
Debt to equity ratio x00.2 20.7%  
Sales to assets ratio x0.40.8 51.9%   
Return on assets %4.910.6 46.4%  
Return on equity %6.918.6 37.2%  
Return on capital %10.019.7 50.8%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m40,81614,722 277.3%   
Fx outflow Rs m30,1437,026 429.0%   
Net fx Rs m10,6737,696 138.7%   
CASH FLOW
From Operations Rs m39,0723,124 1,250.6%  
From Investments Rs m-33,708-8,844 381.1%  
From Financial Activity Rs m-15,3935,026 -306.2%  
Net Cashflow Rs m-7,359-693 1,061.5%  

Share Holding

Indian Promoters % 63.7 74.1 86.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 2.9 176.9%  
FIIs % 23.0 9.1 252.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 13.9 59.7%  
Shareholders   133,026 49,328 269.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  TORRENT PHARMA  PLETHICO PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Recovers after Crashing Over 1000 Points; DHFL Tanks 50%(01:30 pm)

Stock markets in India plunged in the afternoon session today. The BSE Sensex recovered after tanking 1,000 points in intra-day deals.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 21, 2018 03:37 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS